Table 1.
Characteristics of the Study Population
| Characteristics | CD(n=1639) | UC(n=930) | Overall IBD(n=2569) | |
|---|---|---|---|---|
| Mean (SD) or % | Mean (SD) or % | Mean (SD) or % | ||
| Demographics | Age, years | 42 (14) | 42 (14) | 42 (14) |
| Female sex | 72 | 69 | 71 | |
| Race/ethnicity | ||||
| White | 93 | 88 | 91 | |
| African American | 3 | 2 | 3 | |
| Asian | 0.3 | 3 | 2 | |
| Other | 4 | 6 | 5 | |
| Hispanic | 3 | 5 | 4 | |
| Education completed | ||||
| < 12th grade | 1 | 0.4 | 1 | |
| 12th grade | 7 | 5 | 6 | |
| Some college | 22 | 18 | 20 | |
| College | 43 | 43 | 43 | |
| Graduate school | 28 | 34 | 31 | |
| Current smoker | 10 | 8 | 9 | |
| Disease Characteristics | Disease Duration | 15 (12) | 11 (10) | 13 (11) |
| ≥1 hospitalizationsin | 19 | 11 | 16 | |
| the past year | ||||
| ≥1 bowel surgery | 52 | 15 | 39 | |
| IPAA or Koch pouch | 3 | 10 | 6 | |
| Ostomy | 9 | 5 | 7 | |
| sCDAI or SCCAI | 153 (100) | 4 (3) | n/a | |
| SIBDQ | 5 (1) | 5 (1) | 5 (1) | |
| Current Medication Use | 5-aminosalicylates | 34 | 66 | 46 |
| Prednisone | 9 | 13 | 10 | |
| Immunomodulatorsa | 28 | 23 | 26 | |
| Biologic therapyb | 42 | 19 | 34 | |
| General PROMISc Measures | Anxiety | 54 (10) | 55 (9) | 55 (10) |
| Depression | 52 (10) | 52 (10) | 52 (10) | |
| Fatigue | 57 (11) | 55 (11) | 56 (11) | |
| Sleep Disturbance | 52 (9) | 52 (9) | 52 (9) | |
| Satisfaction with Social | 47 (10) | 48 (10) | 48 (10) | |
| Role | ||||
| Pain | 54 (10) | 52 (10) | 53 (10) | |
| Sexually actived | Yes | 76 | 78 | 77 |
| Male | 77 | 78 | 78 | |
| Female | 76 | 79 | 77 |
a
6-mercaptopurine, azathioprine, or methotrexate. deviation is 10. Higher scores indicate more of the domain being measured.
b
Infliximab, adalimumab, certolizumab pegol, or natalizumab.
c
Patient Reported Outcome Information Measurement System items are calibrated so that the mean of the US general population is 50 and the standard.
d
Sexually active within past 30 days.